News

The company has also announced that Michael Powell steps down from the company’s board of directors. Dr Bird will fill the seat held by Dr Powell, a board

Robert Hickey, president and CEO of SyntheMed, said: “SinusShield represents an example of our strategy to capitalize on our proprietary polymer film technology in new surgical applications both

The Nexus-1 and Nexus-2 trials are the company’s pivotal Phase III North American clinical studies for NX-1207. It is anticipated that the trials will enroll over 800 subjects

The partnership focuses on the technological platforms IM and XP-828L developed by Advitech, which have demonstrated in in-vitro and in-vivo preclinical studies the dual ability to accelerate the

The new patents contain claims to a pharmaceutical composition for pain relief containing a narcotic analgesic in micellar form. Rose Perri, COO of Generex, said: “We are pleased

The collaboration has involved shipping frozen samples from two sites in the US to Bangalore for analysis. Peter Berry, president and CEO of CryoPort, said: “Advinus has provided

This strategic collaboration will further the development of Febit’s Geniom technology to detect pathogens more quickly and with increased reliability. The technology development agreement with In-Q-Tel is anticipated

According to the company, NimbleGen comparative genomic hybridization (CGH) 12x135K arrays allow simultaneous analysis of 12 independent sample pairs on a single microarray slide, each with 135,000 empirically

Under the terms of the agreements, in exchange for payment of royalties, Sanofi-Aventis US has agreed to grant Barr and Teva a license to certain patent rights to